-transparent.png){kind=logo}
We examined the ability of sucralfate to prevent secretagogue induced duodenal ulcer in the rat. Sucralfate was administered orally in dosage schedules of 50 mg, 100 mg or 200 mg before and at 3 and 6 hr after commencing a 24 hr continuous infusion of pentagastrin and bethanechol. The animals were sacrificed at 24 hr and the number and severity of ulcers was scored. Ulcers developed in all 9 control rats, in 8 of 9 on the 50 mg dose, in 4 of 9 on the 100 mg dose, and in only 1 of 9 on the 200 mg dose of sucralfate. We conclude that sucralfate prevents the formation of secretagogue induced duodenal ulcer in the rat.
Related Publications
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
September 1987,
The American journal of medicine,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
June 1989,
The American journal of medicine,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
July 1992,
The Journal of the Association of Physicians of India,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
September 1990,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
April 1982,
FDA drug bulletin,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
January 1991,
Scandinavian journal of gastroenterology. Supplement,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
September 1987,
The American journal of medicine,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
August 1991,
The American journal of medicine,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
August 1994,
Bangladesh Medical Research Council bulletin,
C R Smolow, and
S Bank, and
G Ackert, and
C Anfang, and
V Kranz
October 1987,
La Clinica terapeutica,
